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ABSTRACT
KH-type splicing regulatory protein (KHSRP) is a multifunctional RNA-binding 
protein, which is involved in several post-transcriptional aspects of RNA metabolism, 
including microRNA (miRNA) biogenesis. It affects distinct cell functions in different 
tissues and can have an impact on various pathological conditions. In the present 
study, we investigated the oncogenic functions of KHSRP and their underlying 
mechanisms in the pathogenesis of esophageal squamous cell carcinoma (ESCC). 
KHSRP expression levels were elevated in ESCC tumors when compared with 
those in non-tumorous tissues by immunohistochemistry, and cytoplasmic KHSRP 
overexpression was found to be an independent prognosticator for worse overall 
survival in a cohort of 104 patients with ESCC. KHSRP knockdown inhibited growth, 
migration, and invasion of ESCC cells. KHSRP knockdown also inhibited the maturation 
of cancer-associated miRNAs, such as miR-21, miR-130b, and miR-301, and induced 
the expression of their target mRNAs, such as BMP6, PDCD4, and TIMP3, resulting in 
the inhibition of epithelial-to-mesenchymal transition. Our findings uncover a novel 
oncogenic function of KHSRP in esophageal tumorigenesis and implicate its use as a 
marker for prognostic evaluation and as a putative therapeutic target in ESCC.
INTRODUCTION
Esophageal cancer (EC) occurs worldwide with a 
variable geographic distribution. In Asian countries such 
as Japan, esophageal squamous cell carcinoma (ESCC) is 
a major histological type of EC and is one of the most 
aggressive and lethal malignancies [1, 2]. Despite recent 
clinical advances in EC treatment, the overall patient 
prognosis remains poor. Therefore, there remains a 
great deal that needs to be defined, including effective 
screening, diagnosis, and management strategies to guide 
the individualized treatment of ESCC.
KH-type splicing regulatory protein (KHSRP) is 
a multifunctional single-stranded nucleic acid-binding 
protein located in both the nucleus and the cytoplasm. 
KHSRP exerts its numerous cellular functions through the 
modulation of RNA life and gene expression at various 
levels, such as microRNA (miRNA) maturation, alternative 
pre-mRNA splicing, and mRNA localization [3]. 
During miRNA maturation, KHSRP regulates the 
                                                     Research Paper
Oncotarget101131www.impactjournals.com/oncotarget
biogenesis of a subset of miRNAs as a component of 
both Drosha and Dicer complexes in the nuclear and 
cytoplasmic compartments, respectively [4, 5]. Various 
miRNAs have been reported to contribute to multiple 
tumorigenic processes, including cell proliferation, 
invasion, and metastasis, through changing the expression 
of oncogenes and tumor suppressor genes [6]. However, 
the function of KHSRP seems to vary in different cancers 
[7–11], and the roles and mechanisms of KHSRP in the 
tumorigenesis of ESCC remain completely unknown.
In this study, we report that KHSRP exerts 
oncogenic activity in ESCC cells, at least partly, by 
inducing the expression of a set of oncogenic miRNAs, 
including miR-21, miR-130b, and miR-301a, and by 
suppressing the downstream inhibitors of epithelial-to-
mesenchymal transition (EMT), such as BMP6, PDCD4, 
and TIMP3, resulting in the malignant progression of this 
disease.
RESULTS
KHSRP expression and its association with 
clinicopathological characteristics of ESCC
To determine whether KHSRP is involved in 
esophageal carcinogenesis, immunohistochemical (IHC) 
staining with an antibody that specifically recognizes 
KHSRP was performed in surgically resected esophageal 
tissues (Figure 1A). KHSRP immunoreactivity was 
not observed in the cytoplasm and the nucleus of non-
tumorous epithelia. In carcinoma in situ, KHSRP staining 
was observed, predominantly in the nucleus, whereas it 
was observed in both the cytoplasm and the nucleus in 
advanced ESCC tumors. A similar pattern of KHSRP 
immunoreactivity was observed in squamous cell 
carcinomas of other tissues (Supplementary Figure 1A).
We then examined the clinicopathological 
significance of KHSRP expression in primary ESCC 
tumors based on the IHC staining patterns. Among the 104 
ESCC cases without preoperative chemotherapy, positive 
cytoplasmic and nuclear KHSRP immunoreactivities 
were observed in 59 (56.7%) and 68 (65.4%) cases, 
respectively, based on their intensity scores (Table 1). No 
significant association was observed between any of the 
clinicopathological factors and cytoplasmic or nuclear 
KHSRP immunoreactivity, except for histological grading. 
However, venous invasion (v) and the depth of tumor 
invasion (pT) tended to be associated with cytoplasmic 
and nuclear KHSRP immunoreactivities. Notably, Kaplan–
Meier survival estimates showed that positive cytoplasmic 
KHSRP immunoreactivity was significantly associated 
with worse overall survival (P = 0.003), whereas nuclear 
KHSRP immunoreactivity was not (Figure 1B). Similarly, 
positive cytoplasmic KHSRP immunoreactivity tended 
to be associated with worse recurrence-free survival 
probability (P = 0.053), whereas nuclear KHSRP 
immunoreactivity was not (Supplementary Figure 1B). 
In the Cox proportional hazards regression model, 
cytoplasmic KHSRP immunoreactivity and pT and 
N stage (pN) categories were statistically significant 
prognosticators for overall survival by univariate analyses 
(Table 2). Multivariate analyses showed that cytoplasmic 
KHSRP immunoreactivity and pT and pN categories were 
independent predictive factors regardless of the models 
used, suggesting that overexpressed KHSRP was involved 
in the development and/or progression of ESCC through 
cytoplasmic localization. Therefore, we examined the 
expression level and function of KHSRP in a panel of 
ESCC cell lines.
Involvement of KHSRP in ESCC cell function
KHSRP mRNA overexpression was detected in 27 
out of the 45 ESCC cell lines when compared with normal 
esophagus (control) by quantitative real-time PCR (qPCR, 
Supplementary Figure 2A). In contrast, KHSRP protein 
overexpression was detected in most ESCC cell lines 
compared with normal esophageal mucosa, although the 
pattern of KHSRP protein expression levels was similar to 
that of KHSRP mRNA and discrepancies between mRNA 
and protein levels were observed in some cell lines to 
some extent (Supplementary Figure 2B).
To gain insight into the potential functions of 
KHSRP, the overexpression of which could contribute to 
esophageal carcinogenesis, we first tested the effects of 
KHSRP-specific small interfering RNAs (siRNAs) on cell 
proliferation using cell lines with relatively high KHSRP 
expression. By silencing endogenous KHSRP using three 
different siRNAs (Figure 2A and 2B), cell proliferation 
was slightly, but significantly, suppressed in ESCC cells 
(Figure 2C). Knockdown of endogenous KHSRP also 
inhibited spheroid formation in anchorage-independent in 
vitro 3D cell culture (Figure 2D). Protein levels of cell 
cycle inhibitors (p21WAF1/Cip1 and p27Kip1) were increased by 
knocking down endogenous KHSRP (Figure 2E), although 
discrepancies between their mRNA and protein levels 
were observed (Supplementary Figure 3A).
We then assessed the effect of KHSRP knockdown 
on cell mobility and invasion using scratch-wound healing 
and Transwell assays. Scratch-wound healing assays 
revealed that wound closure occurred at a slower rate in 
KHSRP-knockdown ESCC cells when compared with 
control cells (Figure 2F and Supplementary Figure 3B). 
In Transwell assays, uncoated and Matrigel-coated 
membranes were used to examine cell migration and 
invasion, respectively. Transwell assays showed that the 
number of KHSRP siRNA-transfected cells that migrated 
into or invaded the lower chamber was significantly lower 
than that of control cells (Figure 2G, Supplementary 
Figure 3C and 3D). Elevated and reduced expression 
of the epithelial marker (CDH1) and EMT inducer 
(ZEB1) proteins, respectively, were observed in KHSRP-
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knockdown cells when compared with control cells by 
both Western blot analysis (Figure 2H) and fluorescent 
immunocytochemical staining (Supplementary Figure 3E).
To determine the chronic effects of exogenously 
overexpressed KHSRP on ESCC cell function in vitro, 
we established stable transfectants that expressed HA-
tagged KHSRP protein using KYSE1190 and KYSE1250 
cells with relatively low expression of endogenous 
KHSRP (Figure 3A and 3B). Western blot analysis using 
subcellular components obtained by cell fractionation 
showed that exogenously expressed KHSRP was detected 
in both nuclear and cytoplasmic lysates, although 
most KHSRP was located in the nucleus (Figure 3C). 
Stable expression of KHSRP slightly, but significantly, 
increased cell proliferation compared with control cells 
(Figure 3D). Scratch-wound healing assays indicated an 
induction of faster wound closure in KHSRP-expressing 
cells compared with control cells (Figure 3E). Transwell 
assays showed that the number of cells that migrated into 
or invaded the lower chamber was significantly higher 
for KHSRP-expressing cells than for control cells under 
both conditions (Figure 3F). Higher ZEB1 expression 
and lower p21WAF1/Cip1, p27Kip1 and/or CDH1 expression 
were observed in cells exogenously expressing KHSRP, 
when compared with cells lacking exogenous KHSRP 
expression (Figure 3G).
Identification of putative target miRNAs for 
KHSRP
Because KHSRP seemed to exert a greater effect on 
migration/invasion than on the proliferation of the ESCC 
cells, we further investigated the molecular mechanisms of 
KHSRP-promoted ESCC cell migration/invasion. KHSRP 
has been shown to promote maturation of miRNAs by 
binding their conserved sequences in the terminal loop 
[12] and then to alter TGFβ-induced EMT [10]. Therefore, 
we screened differentially expressed genes (mRNA) and 
Table 1: Association between clinicopathological characteristics and KHSRP expression
Clinicopathological factors n
KHSRP immunoreactivity (Cytoplasm)
P valuea
KHSRP immunoreactivity (Nucleus)
P valuea
High (%) Low (%) High (%) Low (%)
Total 104 59 (56.7) 45 (43.3) 68 (65.4) 36 (34.6)
Gender     
Male 85 46 (54.1) 39 (45.9) 0.3116 54 (63.5) 31 (36.5) 0.5944 
Female 19 13 (68.4) 6 (31.6) 14 (73.7) 5 (26.3)
Age  
Mean  ± SD (yr)      64.1 ± 8.4 63.2 ± 7.6 65.3 ± 9.3 0.2031 64.1 ± 8.1 64.1 ± 9.1 0.9758 
Histopathological grading
Well and moderately 
differentiated
75 43 (57.3) 32 (42.7) 1.0000 44 (58.7) 31 (41.3) 0.0227 
Poorly differentiated 29 16 (55.2) 13 (44.8) 24 (82.8) 5 (17.2)
Lymphatic invasion (ly)
Negative 45 23 (51.1) 22 (48.9) 0.3263 31 (68.9) 14 (31.1) 0.5397 
Positive 59 36 (61.0) 23 (39.0) 37 (62.7) 22 (37.3)
Venous invasion (v) 
Negative 73 37 (50.7) 36 (49.3) 0.0828 44 (60.3) 29 (39.7) 0.1166 
Positive 31 22 (71.0) 9 (29.0) 24 (77.4) 7 (22.6)
Depth of tumor invasion (pT)
pT1 56 27 (48.2) 29 (51.8) 0.0747 32 (57.1) 24 (42.9) 0.0654 
pT2-4 48 32 (66.7) 16 (33.3) 36 (75.0) 12 (25.0)
N stage (pN)
pN0 55 32 (58.2) 23 (41.8) 0.8435 35 (63.6) 20 (36.4) 0.8367 
pN1-3 49 27 (55.1) 22 (44.9) 33 (67.3) 16 (32.7)
pStage
pI 43 23 (53.5) 20 (46.5) 0.6882 24 (55.8) 19 (44.2) 0.0976 
 pII-VI 61 36 (59.0) 25 (41.0) 44 (72.1) 17 (27.9)
Statistically significant values are in boldface type.
aP values are from χ2 or Fisher’s exact test and were statistically significant at < 0.05.
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miRNAs in KHSRP-knockdown KYSE850 cells using 
a microarray analysis. In these cells, 560 and 750 genes 
were up- and down-regulated, respectively, by > 1.5-fold 
compared with control cells (Supplementary Tables 1 
and 2). KHSRP knockdown also lowered the expression 
of 26 miRNAs by > 0.5-fold compared with control cells 
(Table 3). Among these miRNAs, the KHSRP knockdown-
induced down-regulation was successfully validated with 
five cancer-associated miRNAs in three ESCC cell lines 
(Figure 4A).
Three (miR-21, miR-130b, and miR-301a) of these 
were chosen for further analysis according to their known 
functions in EMT [13–15]. In 22 KHSRP-overexpressing 
ESCC cell lines, higher expression levels of miR-21, 
miR-130b, and miR-301a were detected in 6, 11, and 
22 lines, respectively, when compared with the normal 
esophagus (Supplementary Figure 4A–4C). In KHSRP-
knockdown cells, on the other hand, the expression levels 
of their primary miRNA precursors (pri-miRNAs) and 
precursor miRNAs (pre-miRNAs) were significantly 
increased compared with control cells (Figure 4B and 4C). 
Ribonucleoprotein immunoprecipitation (RIP), which 
was conducted using nuclear or cytoplasmic lysates 
prepared from HEK293 cells transiently expressing Halo-
tagged KHSRP, followed by qPCR demonstrated the 
bindings of nuclear and cytoplasmic KHSRP to these pri-
miRNAs (Supplementary Figure 5A) and pre-miRNAs 
(Supplementary Figure 5B), respectively. Taken together, 
these results suggested that KHSRP is mainly involved 
in multiple maturation steps of these three miRNAs to 
increase their expression levels in ESCC.
Among 560 up-regulated genes in KHSRP-
knockdown cells, a total of 77 mRNAs were predicted as 
target genes for at least one of these three miRNAs using 
DIANA-TarBase v7.0 database (http://diana.imis.athena-
innovation.gr/DianaTools/index.php?r=tarbase/index): 40, 
39 and 43 mRNAs for miR-21, miR-130b and miR-301a, 
respectively (Supplementary Table 3). Pathway analysis of 
these 77 mRNAs using the Kyoto Encyclopedia of Genes 
and Genomes (KEGG) database ranked “TGFβ signaling 
pathway” and “endocytosis” as functional pathways 
with nominal P-values < 0.05. However, only “TGFβ 
Figure 1: KHSRP protein expression/localization and its association with overall survival in primary ESCC tumors. 
(A) Representative images of immunohistochemically detected KHSRP protein in normal mucosa, carcinoma in situ, and advanced 
squamous cell carcinoma of the esophagus. Scale bars, 100 μm. (B) Kaplan–Meier curves for the overall survival rates of 104 ESCC 
patients according to the cytoplasmic (left) and nuclear (right) immunoreactivities of KHSRP.
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signaling pathway” was ranked as a functional pathway 
with adjusted P-value < 0.25 (Table 4). Of the transcripts 
annotated as “TGFβ signaling pathway” and reported as 
regulators of EMT, we focused on 12 genes (BMP6, BTG2, 
CD2AP, EPHA4, EZH1, LTBP1, MXD1, NEO1, PDCD4, 
RFFL, SDC4 and TIMP3) for further analysis according 
to their known functions in cancers [13, 16–26]. Increased 
expression levels of these genes in KHSRP-knockdown 
cells were successfully validated by qPCR (Figure 4D 
and Supplementary Figure 5C). The effects of the KHSRP 
silencing on protein expression levels were assessed with 
BMP6, PDCD4, and TIMP3 genes according to their 
known functions in EMT. Compared with control siRNA-
treated cells, KHSRP siRNA-treated cells exhibited higher 
levels of BMP6, PDCD4, and TIMP3 proteins (Figure 4E 
and Supplementary Figure 5D). Conversely, cells that 
stably overexpressed HA-tagged KHSRP showed higher 
levels of miR-21, miR-130b, and miR-301a (Figure 4F) 
and lower levels of BMP6, PDCD4, and TIMP3 mRNAs 
and proteins compared with control cells (Figure 4G and 
Supplementary Figure 5E). We validated correlations 
among expression levels of KHSRP, these three miRNAs, 
and their target mRNAs in surgically resected ESCC 
tumors, whose high-quality RNA was available for qPCR. 
In two ESCC tumors with positive cytoplasmic KHSRP 
immunoreactivity, miR-21, miR-130b, and miR-301a 
expression levels in tumors were higher and BMP6, 
PDCD4, and TIMP3 mRNA expression levels were lower 
compared with those in paired non-tumorous tissues, 
whereas these alterations were not consistently observed 
in two ESCC tumors with negative cytoplasmic KHSRP 
immunoreactivity (Supplementary Figure 6A, 6B).
Functional association between KHSRP-targeted 
miRNAs and their putative target mRNAs
The proteins encoded by BMP6, PDCD4, and 
TIMP3 are known as inhibitors of EMT [13, 16, 26–29]. 
Therefore, we next tested whether increased KHSRP 
expression down-regulates their cognate protein levels 
in ESCC cells by up-regulating miR-21, miR-130b, and/
or miR-301a. Exogenous introduction of each of the 
miRNA inhibitors into cells with relatively high KHSRP 
expression induced higher levels of BMP6, PDCD4 and/or 
TIMP3 proteins (Figure 5A) and mRNAs (Figure 5B) and 
inhibited cell migration (Figure 5C and Supplementary 
Table 2: Cox proportional hazard regression analysis for overall survival
Factor
Univariate Multivariatea
Model 1 Model 2
Hazard 
ratio
95% confidence 
interval
P value P value P value
Gender     
  Male versus Female 1.32 0.5552 - 3.9080 0.5518 0.5802 -
Age (years) 
  ≥ 65 versus < 65 1.06 0.5285 - 2.1734 0.8684 0.2886 -
Histopathological grading 
  Poorly versus Well-moderately differentiated 1.27 0.5708 - 2.8320 0.5568 0.5712 -
Lymphatic invasion   
  Positive versus Negative 2.03 0.9880 - 4.4942 0.0541 0.6143 -
Venous invasion
  Positive versus Negative 1.61 0.7646 - 3.2637 0.2018 0.8563 -
Depth of tumor invasion (pT)
  pT2-4 versus pT1 3.27 1.5888 - 7.2324 0.0011 0.0332 0.0229 
N stage (pN)
  pN1-3 versus pN0 3.06 1.4887 - 6.7720 0.0021 0.0069 0.0086 
KHSRP immunoreactivity in the cytoplasm
  Positive versus Negative 3.28 1.4964 - 8.2336 0.0023 0.0045 0.0059 
KHSRP immunoreactivity in the nucleus
  Positive versus Negative 1.37 0.6547 - 3.1225 0.4153 - -
Note: Statistically significant values are in boldface type.
aModel 1, all factors excluding KHSRP immunoreactivity in the nucleus model were included; 
Model 2, a step-wise procedure was used.
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Figure 2: Effects of KHSRP knockdown on cellular function in ESCC cells. (A) ESCC cells with relatively high expression 
of KHSRP (KYSE850, TE5, and TE14) were transfected with 10 nM of control or KHSRP-specific siRNAs for 48 h and KHSRP mRNA 
expression levels were evaluated by qPCR. The values are expressed as fold changes (mean ± SD, n = 6) when compared with the 
respective values in control siRNA-transfected cells. *P < 0.05. (B) ESCC cells were treated as described in Figure 2A, and expression 
levels of KHSRP protein were evaluated by Western blot analysis. (C) ESCC cells were transfected with 10 nM of control or KHSRP-
specific siRNAs for 24 h, and cellular proliferation was measured using a WST-8 assay at the indicated times. The values are expressed as 
fold changes (mean ± SD, n = 6) when compared with the respective values in control cells (0 h). *P < 0.05. (D) For spheroid formation 
assay, ESCC cells treated as described in Figure 2C were seeded in ultra-low attachment 96-well round bottom plates and incubated for the 
indicated times (d, days). The areas of spheroids were determined as described in the Materials and Methods section (mean ± SD, n = 8). 
 *P < 0.05. (E) ESCC cells were treated as described in Figure 2A, and the levels of p21WAF1/Cip1, p27Kip1 and KHSRP proteins were 
determined by Western blot analysis. (F) ESCC cells treated as described in Figure 2C were dispensed into ibidi Culture-Inserts. After 
24 h, the Culture-Inserts were removed, and the scratch-wound area was determined as described in the Materials and Methods section 
(mean ± SD, n = 6). The values are expressed as percentages (mean ± SD, n = 6) when compared with the respective values in control cells 
(0 h). *P < 0.05. (G) ESCC cells treated as described in Figure 2C were added onto BD Falcon Cell Culture Inserts coated with (invasion 
assay) or without (migration assay) Matrigel. After incubation for 48 h, cells on the lower surface of filters were determined as described in 
the Materials and Methods section (mean ± SD, n = 6). *P < 0.05. (H) ESCC cells were treated as described in Figure 2A, and the expression 
levels of ZEB1, CDH1, and KHSRP proteins were evaluated by Western blot analysis.
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Figure 7A) and invasion (Figure 5D and Supplementary 
Figure 7B). In contrast, the exogenous introduction of 
each of the miRNA mimics into KHSRP-knockdown 
cells restored cell growth (Supplementary Figure 7C) and 
cell migration (Supplementary Figure 7D), and inhibited 
the expression levels of BMP6, PDCD4, and TIMP3 
proteins (Supplementary Figure 7E), at least in part. These 
results suggested that overexpressed KHSRP promotes 
ESCC migration and invasion, at least partly, by the up-
regulation of a set of cancer-associated miRNAs and 
by the suppression of their downstream EMT-inhibiting 
proteins.
DISCUSSION
To our knowledge, this is the first report that 
demonstrates the clinical and functional significance 
of KHSRP in ESCC tumorigenesis. Overexpression of 
Table 3: List of the miRNA differentially expressed in KHSRP knockdown cells
miRNA name Fold change
hsa-miR-130b-3p 0.015 
hsa-miR-15a-5p 0.017 
hsa-miR-10a-5p 0.019 
hsa-miR-324-3p 0.021 
hsa-miR-29c-3p 0.022 
hsa-miR-26a-5p 0.031 
hsa-miR-151b 0.038 
hsa-miR-30a-5p 0.039 
hsa-miR-185-5p 0.040 
hsa-miR-30e-5p 0.044 
hsa-miR-181a-5p 0.045 
hsa-miR-301a-3p 0.045 
hsa-miR-30b-5p 0.047 
hsa-miR-18b-5p 0.073 
hsa-miR-130a-3p 0.277 
hsa-miR-27b-3p 0.319 
hsa-miR-22-3p 0.327 
hsa-miR-331-3p 0.329 
hsa-miR-16-5p 0.340 
hsa-miR-15b-5p 0.377 
hsa-miR-21-5p 0.388 
hsa-miR-31-5p 0.407 
hsa-miR-29a-3p 0.410 
hsa-miR-31-3p 0.433 
hsa-let-7e-5p 0.449 
hsa-let-7b-5p 0.466 
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KHSRP in tumor cells, particularly in the cytoplasm, 
was an independent prognosticator for overall survival. 
KHSRP mainly promoted cell migration/invasion with 
minimal induction of ESCC cell proliferation. Many 
studies in the past 20 years have demonstrated that 
KHSRP-dependent regulation of RNA metabolism affects 
distinct cell functions in different tissues and can have an 
impact on pathological conditions. However, very few 
reports have described KHSRP function in the context 
of human carcinomas. The overall role of KHSRP in 
Figure 3: KHSRP overexpression promotes ESCC cell migration and invasion. (A) Levels of endogenous KHSRP and 
exogenous HA-tagged KHSRP proteins in ESCC cells with relatively low expression of endogenous KHSRP (KYSE1190 and KYSE1250) 
that stably express HA-tagged exogenous KHSRP were analyzed by Western blot analysis. (B) Representative images of ESCC cells stably 
expressing HA-tagged exogenous KHSRP detected by FIC with an anti-HA antibody (green). Nuclei were counterstained with DAPI (blue). 
Scale bars, 20 μm. (C) Subcellular distribution of exogenously expressed KHSRP. Cytoplasmic and nuclear fractions were prepared from 
KYSE1190 and KYSE1250 cells stably expressing HA-tagged KHSRP. Exogenously expressed KHSRP, α-tubulin (cytoplasmic marker), 
and hnRNPC1/C2 (nuclear marker) were detected by Western blot analysis. (D) The number of viable cells of each stable transfectant was 
assessed using a WST assay at the indicated times. The values are expressed as fold changes (mean ± SD, n = 6) when compared with the 
respective control values (0 h). *P < 0.05. (E) Each stable transfectant was dispensed into the ibidi Culture-Inserts. The area of the scratch-
wound was determined as described in Figure 2F. The values are expressed as percentages (mean ± SD, n = 6) when compared with the 
respective values in control cells (0 h). *P < 0.05. (F) Each stable transfectant was transferred into the upper chamber of BD Falcon Cell 
Culture Inserts coated with (invasion assay) or without (migration assay) Matrigel. After incubation for 48 h, cells on the lower surface of 
filters were determined as described in Figure 2G (mean ± SD, n = 3). *P < 0.05. (G) Levels of endogenous KHSRP, exogenous HA-tagged 
KHSRP, ZEB1, CDH1, p21WAF1/Cip1, and p27Kip1 proteins were measured by Western blot analysis.
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carcinogenesis has been controversial, because KHSRP 
exerts oncogenic or tumor suppressive functions through 
various mechanisms in different cancer types. It has been 
reported that KHSRP promotes cell motility in human 
liver cancer [7, 30] and osteosarcoma [31] cells, and 
promotes cell proliferation, but not migration, in small 
cell lung cancer cells [11]. In contrast, Yang et al. showed 
the suppressive effects of KHSRP on migration ability 
of glioblastoma cells [9]. In addition, two independent 
studies have demonstrated that high KHSRP expression 
levels were associated with longer overall survival in 
glioblastoma multiforme [9, 32]. Because some RNA-
binding proteins can act as both positive and negative 
post-transcriptional regulators in cell type-specific 
manner [33–36], the finding that KHSRP could work as 
an oncogene in ESCC was not surprising. It is evident that 
the consequences of altered KHSRP levels are different 
in distinct tumors and may reflect cell-restricted functions 
of KHSRP that rely on the participation of the protein 
in distinct multiprotein complexes and on its binding to 
various targets in different cell lineages [3].
miRNAs, the maturation of which is enhanced 
by KHSRP, play important roles in controlling various 
cellular functions. Although numerous studies over the past 
decade have shown cell type-specific changes in miRNA 
expression profiles, knowledge of the mechanisms that 
underlie their deregulation in ESCC is still limited [6, 37]. 
We observed deregulated maturation of the potential target 
miRNAs with an increase in their precursors in KHSRP-
knockdown cells. Some of these have been reported to 
exert cancer-associated functions [6, 37], indicating that 
deregulation of KHSRP-miRNA interplay may, at least in 
part, affect the ESCC-specific miRNA expression profile. It 
has been demonstrated that KHSRP binds to the conserved 
G-rich elements in the terminal loop of a cohort of miRNA 
precursors and promotes their maturation by facilitating 
their association with Drosha in the nucleus or with Dicer 
in the cytoplasm [12]. Indeed, the bindings of nuclear and 
cytoplasmic KHSRP to pri-miRNAs and pre-miRNAs of 
the three miRNAs, respectively, were detected by our RIP-
qPCR experiments. However, none of the three miRNAs 
that we identified as KHSRP targets in ESCC has typical 
G-rich elements, such as GGG triplets, in the terminal 
loop of their precursors. Notably, it has been demonstrated 
that KHSRP is bound to the precursor of miR-21, and its 
knockdown reduced the expression levels of mature miR-
21 in HeLa and NIH3T3 cells [12]. Therefore, it remains 
unclear whether KHSRP increases the expression levels of 
these three miRNAs through known mechanisms.
The comprehensive elucidation of molecules that 
execute the EMT program still remains an important 
question in the field of cancer research, because the 
identification of key molecules within this network is 
critical from a therapeutic perspective. We demonstrated 
that KHSRP induced EMT by the up-regulation of 
oncogenic miRNAs, such as miR-21, miR-130b, and 
miR-301a. Overexpression of miR-21 is known to induce 
EMT by targeting PDCD4 [13, 27, 28] and TIMP3 [26, 
29] mRNAs in various cancer types, including ESCC. 
EMT-suppressor BMP6 is a known target of miR-130b 
and miR-301a [38]. Therefore, KHSRP coordinates the 
expression of a gene cluster that encodes proteins within 
EMT-related and/or TGFβ signaling pathways. This 
suggests that KHSRP could be a possible therapeutic 
target for simultaneous and efficient manipulation 
of various target genes/pathways contributing to the 
malignant progression of ESCC. However, in contrast to 
our findings, several studies have revealed suppressive 
effects of KHSRP on EMT in murine immortalized 
mammary epithelial cells [10, 39] and laryngeal squamous 
cell carcinoma cells [40].
In addition to miRNA maturation, KHSRP plays 
crucial roles in a variety of cellular processes, such as 
alternative pre-mRNA splicing and mRNA localization. 
Therefore, it is possible that oncogenic functions of 
overexpressed KHSRP in ESCC cells are also mediated 
through regulation of these processes. In KHSRP-
overexpressing ESCC cells, inhibition of each of the 
endogenously expressed target miRNAs released the up-
regulation of the corresponding targets at both mRNA and 
protein expression levels, and inhibited cell migration/
invasion (Figures 5A–5D), whereas introduction of 
each of the miRNA mimics into KHSRP-knockdown 
cells inhibited expression levels of the corresponding 
target proteins and restored cell migration, at least 
partly. However, each of the three miRNAs decreased 
expression levels of tested genes other than their possible 
direct targets in ESCC cells (Figure 5A, Supplementary 
Figure 7E). These results suggested that the effects of 
overexpressed KHSRP on EMT in ESCC cells could 
be explained by direct and indirect miRNA-mediated 
pathways shown in Figure 5E. In addition, it is possible 
that KHSRP employs various strategies involving other 
than these three miRNAs and/or their targets to promote 
EMT of ESCC, because the effects of KHSRP on the 
expression of EMT-related molecules, including ZEB1, 
CDH1, BMP6, PDCD4, and TIMP3, were different among 
the selected ESCC cell models. KHSRP has been reported 
Table 4: Functional pathways of 77 target mRNAs of miR-21, miR-130b and miR-301a 
Term P value Adjusted P value (FDR)
hsa04350 TGF-beta signaling pathway 0.003 0.117
hsa04144 Endocytosis 0.025 0.388
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Figure 4: Effects of KHSRP knockdown or overexpression on the expression of putative target miRNAs and protein 
levels of their target genes in ESCC cells. (A) ESCC cells were transfected with 10 nM of control or KHSRP-specific siRNAs for 48 
h, and the amounts of miR-21, miR-31, miR-130b, miR-151b, and miR-301a were separately measured by qPCR. The values are expressed 
as fold changes (mean ± SD, n = 6) when compared with the respective values in control siRNA-transfected cells. *P < 0.05. (B) ESCC 
cells were treated as described in Figure 4A, and the expression levels of pri-miR-21, pri-miR-130b, and pri-miR-301a were measured 
by qPCR of control or KHSRP-specific siRNAs. The values are expressed as fold changes (mean ± SD, n = 6) when compared with the 
respective values in control siRNA-transfected cells. *P < 0.05. (C) ESCC cells were treated as described in Figure 4A, and expression 
levels of pre-miR-21, pre-miR-130b, and pre-miR-301a were measured by qPCR of control or KHSRP-specific siRNAs. The values are 
expressed as fold changes (mean ± SD, n = 3) when compared with the respective values in control siRNA-transfected cells. *P < 0.05. 
(D) KYSE850 cells were treated as described in Figure 4A, and the expression levels of the 12 putative target mRNAs for miR-130b, 
miR-21, and miR-301a were measured by qPCR. The values are expressed as fold changes (mean ± SD, n = 6) when compared with the 
respective values in control siRNA-transfected cells. *P < 0.05. (E) KYSE850 cells were treated as described in Figure 4A, and the levels 
of BMP6, PDCD4, TIMP3, and KHSRP proteins were measured by Western blot analysis. (F) The levels of miR-21, miR-130b, and 
miR-301a in total RNA prepared from ESCC cells overexpressing exogenous KHSRP were measured by qPCR. The values are expressed 
as fold changes (mean ± SD, n = 6) when compared with the respective values in control cells (mock). *P < 0.05. (G) The levels of BMP6, 
PDCD4, TIMP3, endogenous KHSRP, and exogenous HA-tagged KHSRP proteins in lysates prepared from ESCC cells overexpressing 
exogenous KHSRP were measured by Western blot analysis.
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to predominantly induce cell proliferation in small cell 
lung cancer cells by promoting maturation of miR-26a and 
inhibiting the expression of its target, PTEN [11]. In our 
study, the effect of KHSRP on proliferation was minimal 
in ESCC cells, albeit significant. These results suggested 
that the miRNA maturation-mediated pathway may be 
important for oncogenic functions of KHSRP regardless 
of its effects on each malignant phenotype.
Figure 5: Effects of putative KHSRP target miRNAs on the expression levels of their target mRNAs and ESCC cellular 
function. (A) ESCC cells were transfected with 30 nM of each of the miRNA-specific inhibitors or control for 48 h. The levels of BMP6, 
PDCD4, TIMP3, and KHSRP proteins were measured by Western blot analysis. (B) ESCC cells were treated as described in Figure 5A, 
and the levels of BMP6, PDCD4, and TIMP3 mRNAs were measured by qPCR. The values are expressed as fold changes (mean ± SD, 
n = 6) when compared with the respective values in control inhibitor-transfected cells. *P < 0.05. (C, D) ESCC cells were transfected 
with 30 nM of each of the miRNA-specific inhibitors or control for 24 h were added onto BD Falcon Cell Culture Inserts coated without 
(migration assay; C) or with (invasion assay; D) Matrigel. After incubation for 48 h, cells on the lower surface of filters were determined 
as described in Figure 2G (mean ± SD, n = 3). *P < 0.05. (E) Model depicts the proposed mechanism whereby KHSRP promotes EMT.
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In conclusion, our study suggests that 
overexpression of KHSRP is involved in the pathogenesis 
of ESCC by inducing the aggressive phenotype of ESCC 
cells. KHSRP mainly enhances tumor cell migration 
and invasion by promoting the maturation of miR-130b, 
miR-21 and miR-301a and by indirectly inhibiting the 
expression of their targets, such as endogenous EMT 
inhibitors BMP6, PDCD4 and TIMP3. Our findings 
uncover a novel oncogenic function of KHSRP in 
esophageal tumorigenesis and implicate its use as a marker 
for prognostic evaluation and as a putative therapeutic 
target in ESCC. However, molecular mechanisms that 
underlie upstream and downstream pathways of KHSRP-
mediated cellular functions in esophageal carcinogenesis 
remain unclear. In ESCC cell lines, increased expression 
of the KHSRP protein compared with normal esophagus 
was more prominently observed than that of the KHSRP 
mRNA, suggesting that undiscovered mechanisms 
causing hyperinduction of the KHSRP protein, such as 
enhanced translation and protein stabilization, contribute 
to overexpression and activation of oncogenic KHSRP 
in ESCC. Overexpressed KHSRP could bind to miRNA 
precursors in both the nucleus and the cytoplasm, 
but cytoplasmic localization of KHSRP seems to be 
associated with a more malignant phenotype of tumors 
in patients with ESCC, suggesting that yet undiscovered 
mechanisms of cytoplasmic KHSRP may also contribute 
to its tumorigenic functions. Further studies investigating 
those mechanisms are necessary, not only to develop 
interventional methods for targeting KHSRP, but also 
to explore more appropriate potential biomarkers and 
therapeutic targets for this disease.
MATERIALS AND METHODS
Cell lines and primary tissue samples
A total of 45 ESCC cell lines were used, of which 34 
belonged to the KYSE cell line series that were established 
from surgically resected tumors [41] and obtained from 
Dr. Yutaka Shimada, or were provided by the Japanese 
Collection of Research Bioresources (JCRB, Ibaraki, 
Japan); 10 cell lines were from the TE series provided 
by the Cell Bank, RIKEN BioResource Center (Tsukuba, 
Japan), and T.T was provided by JCRB.
ESCC tumor samples were obtained from 104 
patients with histologically proven primary ESCC, 
who underwent esophagectomy (potentially curative 
R0 resection) without neoadjuvant therapy at Kyoto 
Prefectural University of Medicine Hospital (Kyoto, 
Japan) between 1998 and 2011 and at Tokushima 
University Hospital (Tokushima, Japan) between 2005 
and 2011. Samples were embedded in paraffin after 
24 h of formalin fixation. No patients had synchronous or 
metachronous multiple cancers in other organs. Relevant 
clinical and survival data were available for all patients. 
In this series, all M1 tumors had distant lymph node 
metastases, but no organ metastasis. Disease stage was 
defined in accordance with the International Union against 
Cancer tumor–lymph node–metastases classification [42]. 
The median follow-up period for surviving patients was 
40.5 months (ranging from 0.16 to 156.9 months). Formal 
written consent was obtained from all patients after 
approval for all aspects of these studies by the local ethics 
committee (Kyoto Prefectural University of Medicine and 
Tokushima University).
Total RNA was extracted from frozen tumor tissues 
and paired non-tumorous tissues using Allprep RNA/
DNA mini kit (Qiagen, Hilden, Germany) according to 
the manufacturer’s protocol.
Antibodies
Antibodies used in this study are listed in 
Supplementary Table 4.
Immunohistochemistry and scoring
Paraffin sections (4 µm thick) were subjected to 
IHC staining for each protein by using DAKO EnVision+ 
Kit/HRP (Agilent Technologies; Santa Clara, CA, 
USA) for color development with diaminobenzidine 
tetrahydrochloride as described in a previous report [43].
Tumor tissues were compared with non-tumorous 
tissues. The percentage of the total cell population expressing 
the target protein and the overall staining intensity in tumor 
cells were evaluated in each case at 200× magnification. 
The expression of a target protein was considered positive 
when over 10% of the tumor cells showed strong or diffuse 
staining. Nuclear KHSRP staining intensity was considered 
positive when the cells showed stronger staining compared 
with the non-tumorous esophageal cells in the parabasal 
layer, whereas the intensity of cytoplasmic KHSRP staining 
was considered positive when the cells exhibited some 
staining. All stained slides were evaluated blindly and 
independently by two investigators without any knowledge 
of the clinicopathological data, and any discordant results 
were resolved by using a conference microscope.
Quantitative real-time PCR for mRNA, pri-
miRNA, pre-miRNA, and miRNA
For quantification of mRNA and pri-miRNA 
levels, 500 ng of total RNA was reverse-transcribed 
using ReverTra Ace qPCR RT Master Mix with gDNA 
Remover kit (TOYOBO, Osaka, Japan). Transcript levels 
were quantified using specific primer sets (Supplementary 
Table 5) and SYBR Green Master Mix (Applied Biosystems, 
Waltham, MA, USA), as described in a previous report [43], 
or TaqMan kits (Supplementary Table 5) according to the 
manufacturer’s instructions. GAPDH mRNA levels were 
used as an internal control for normalization.
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For quantification of pre-miRNA levels, 500 ng of 
total RNA was used as a template to generate the first-
strand cDNA for pre-miRNA using miScript II RT kit 
(Supplementary Table 5; Qiagen). Transcript levels were 
quantified using miScript Precursor Assay (Qiagen) and 
miScript SYBR Green PCR Kits (Qiagen) according to 
the manufacturer’s instructions. RNU6 snoRNA levels 
were similarly measured and used as an internal control 
for normalization.
For quantification of miRNA levels, 10 ng of total 
RNA was used as a template to generate specific first-
strand cDNA for miRNAs using a TaqMan-specific 
miRNA reverse transcription kit (Supplementary Table 5; 
Applied Biosystems). RNU44 snoRNA levels were 
similarly measured and used as an internal control for 
normalization.
Western blot analysis
Whole-cell lysate preparation and Western blot 
analysis using GAPDH as a loading control were performed 
as previously described [43]. Images were obtained with 
a GE Amersham Imager 600 (GE Healthcare, Milwaukee, 
WI, USA), and band intensities were quantified using 
ImageQuant TL 8.1 software (GE Healthcare).
Subcellular components were isolated using a 
LysoPure Nuclear and Cytoplasmic Extractor kit (Wako 
Pure Chemical Industries, Osaka, Japan) according to the 
manufacturer’s instructions.
Fluorescent immunocytochemistry (FIC)
Cells were cultured on chamber slides, fixed in 4% 
paraformaldehyde for 10 min at room temperature and 
permeabilized with 0.1% Triton X-100 in phosphate-
buffered saline for 10 min at room temperature. FIC 
was performed as described previously [43]. After 
mounting using ProLong Gold Antifade Reagent with 
4′,6-diamidino-2-phenylindole (DAPI), cells were 
observed under a fluorescence microscope (LSM510; Carl 
Zeiss, Oberkochen, Germany).
Plasmid construction
The N-terminal HA-tagged full coding sequence 
of human KHSRP (NM_022037) was amplified by PCR 
(Supplementary Table 5) using Halo-tagged KHSRP 
expression plasmid, pFN21AE2201, obtained from 
Kazusa DNA Research Institute (Chiba, Japan), and 
cloned into the retroviral vector pMXs-Neo (Cell Biolabs, 
San Diego, CA, USA).
Transient transfection experiments
siRNAs targeting mRNA of KHSRP (#1–3), or 
control siRNAs (Supplementary Table 6) were transfected 
into cells at a final concentration of 10 nM. The inhibitor 
for each miRNA or a negative control (Supplementary 
Table 6) was transfected at a final concentration of 30 nM 
using Lipofectamine RNAiMax reagent (Invitrogen, 
Carlsbad, CA, USA) according to the manufacturer’s 
instructions.
Stable transfection experiments
To establish ESCC cell lines stably overexpressing 
KHSRP, cells were infected with HA-tagged KHSRP-
expressing retroviruses and selected by treatment with 0.5 
mg/mL of G418 for 4 weeks. Control cells were obtained 
using retroviruses obtained from the empty pMXs-
Neo vector that was packaged in PLAT-A cells. Crude 
transfectants were subcultured and tested for exogenous 
KHSRP overexpression using an anti-HA antibody.
Cell proliferation
Cell growth was assessed at the indicated times 
after seeding (2 × 104 cells/24-well plate) using a water-
soluble tetrazolium (WST) salt assay (Cell Counting 
Kit-8; Dojindo, Mashikimachi, Japan) according to the 
manufacturer’s instructions. The results are expressed as 
the mean absolute absorbance at the indicated time divided 
by the mean absolute absorbance of each sample cultured 
for 24 h after seeding.
Spheroid formation was performed as described 
previously [44]. Briefly, 100 μL/well of cell suspensions 
(1000 cells/mL) were dispensed into PrimeSurface 
96-well round-bottomed plates (Sumitomo Bakelite, 
Tokyo, Japan). Plates were centrifuged for 5 min at 200 × g 
and incubated at 37°C in an atmosphere of 5% CO2. The 
areas of formed spheroids were determined using ImageJ 
software (http://imagej.nih.gov/ij/).
Scratch-wound healing assay
The transfectants were dispensed into the ibidi 
Culture-Inserts (ibidi GmbH, Munich, Germany). After 
24 h, the Culture-Inserts were removed, and the area of the 
wound was observed under a microscope. The remaining 
scratch areas were analyzed with ImageJ software. The 
migration rate was determined as a percentage reduction 
of the initial scratch area.
Transwell migration and invasion assays
Transwell migration and invasion assays were 
carried out in 24-well modified Boyden chambers (BD 
transduction, Franklin Lakes, NJ). The upper surface of 
the 6.4 mm diameter filters with 8 μm pores was pre-
coated with (invasion assay) or without (migration assay) 
Matrigel (BD transduction). Transfectants (5 × 104 cells/
well) were transferred into the upper chamber. Following 
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48 h of incubation, migrated or invasive cells on the lower 
surface of filters were fixed and stained with Diff-Quik 
stain (Sysmex, Kobe, Japan). Stained cell nuclei were 
counted in triplicates. We assessed the migration and 
invasive potential of each transfectant by calculating the 
ratio of the percentages to their control counterparts.
Microarray analysis
Total RNA for gene expression analysis was isolated 
using RNA-Iso Plus reagent (Takara, Shiga, Japan), 
whereas total RNA for miRNA expression analysis 
was isolated using NucleoSpin miRNA kit (Takara). 
Microarray data for mRNAs and miRNAs were obtained 
using a whole human genome microarray or a human 
miRNA microarray (8 × 60 k, Agilent Technologies), 
respectively, as described previously [43, 45], and 
analyzed using GeneSpring 13.0 software (Agilent 
Technologies). All microarray data are available at the 
Gene Expression Omnibus (GSE99422, GSE99423).
Predicted targets for these differentially expressed 
miRNAs were identified using TarBase v7.0 (http://www.
microrna.gr/tarbase) to provide experimentally validated 
target genes for miRNAs [46].
Enrichment analyses of the set of the predicted target 
genes for differentially expressed miRNAs and functional 
pathways related to this gene set were performed using 
KEGG pathway analysis. Over-representation of specific 
KEGG pathways in a gene set was statistically analyzed 
by DAVID Bioinformatics Resources 6.7 software (http://
david.abcc.ncifcrf.gov/home.jsp) [47, 48]. The nominal 
P-value and the Benjamini–Hochberg false discovery rate 
(adjusted P-value) were used to determine the significance 
of enrichment or over-representation of terms for each 
annotation. 
Ribonucleoprotein immunoprecipitation (RIP)
Immunoprecipitation of ribonucleoprotein 
complexes was performed using a RiboCluster Profiler 
RIP-Assay kit (Medical & Biological Laboratories, 
Nagoya, Japan) according to the manufacturer’s protocol. 
Briefly, HEK293 cells transiently expressing Halo-
tagged KHSRP (KHSRP-Halo) were crosslinked on ice 
by irradiation with UV light (365 nm) at 150 mJ/cm2. 
Cytoplasmic lysates (250 μg protein) or nuclear extracts 
(250 μg protein) were incubated for 3 h at 4°C with 50 µL 
of a 50% (v/v) suspension of HaloLink Resin (Promega, 
Madison, WI, USA). After the resin was treated with 
HaloTEV protease (Promega), the IP immunoprecipitated 
transcripts were quantified by qPCR.
Statistical analysis
The clinicopathological variables pertaining to the 
corresponding patients were analyzed by χ2 or Fisher’s 
exact test. For survival analysis, Kaplan–Meier survival 
curves were constructed for groups based on univariate 
predictors, and differences among the groups were tested 
with the log-rank test. Univariate and multivariate survival 
analyses were performed using the likelihood ratio test of 
the stratified Cox proportional hazards model. Differences 
among subgroups were tested with Student’s t-test or with 
analysis of variance and Tukey’s multiple comparison 
test. Differences were assessed with a two-sided test and 
considered significant at P < 0.05.
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